Valuation: Qiagen NV

Market Cap 8.1B 7.09B 6.53B 6.06B 11.51B 772B 11.67B 78.18B 30.42B 379B 30.4B 29.74B 1,314B P/E 2026 *
17.6x
P/E 2027 * 17.9x
Enterprise Value 8.66B 7.58B 6.98B 6.48B 12.31B 826B 12.47B 83.58B 32.53B 405B 32.5B 31.79B 1,405B EV / Sales 2026 *
4.02x
EV / Sales 2027 * 3.68x
Free-Float
99.27%
Yield 2026 *
-
Yield 2027 * 0.48%
Manager TitleAgeSince
Chief Executive Officer 61 07/10/2019
Director of Finance/CFO 58 01/01/2004
Chief Operating Officer - 01/04/2022
Director TitleAgeSince
Director/Board Member 77 01/06/2011
Director/Board Member 60 08/01/2021
Director/Board Member 72 23/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
+0.40%+7.15%+4.80%+11.39% 50.25B
+0.40%-1.37%+401.69%+625.15% 40.39B
-0.52%+6.57%+25.41%-5.37% 34.38B
+3.97%+6.71%+26.06%+63.36% 34.4B
-4.19%-1.84%+3.76%+32.17% 26.32B
-2.40%+1.60% - - 16.64B
+1.34%+5.68%+75.77%+141.51% 16.14B
+1.08%+1.28%+15.20%+22.38% 13.71B
+1.69%+3.09%+93.44%+99.19% 13.75B
Average +0.20%+3.57%+80.77%+123.72% 27.33B
Weighted average by Cap. +0.26%+4.03%+91.79%+142.23%

Financials

2026 *2027 *
Net sales 2.16B 1.89B 1.74B 1.61B 3.06B 206B 3.11B 20.81B 8.1B 101B 8.09B 7.92B 350B 2.27B 1.99B 1.83B 1.7B 3.23B 217B 3.27B 21.93B 8.54B 106B 8.53B 8.34B 369B
Net income 423M 370M 341M 317M 602M 40.35B 610M 4.08B 1.59B 19.81B 1.59B 1.55B 68.68B 472M 413M 380M 353M 671M 44.99B 680M 4.55B 1.77B 22.08B 1.77B 1.73B 76.56B
Net Debt 559M 490M 451M 419M 795M 53.34B 806M 5.4B 2.1B 26.18B 2.1B 2.05B 90.78B 271M 238M 219M 203M 386M 25.89B 391M 2.62B 1.02B 12.71B 1.02B 997M 44.06B
Logo Qiagen NV
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-